- Increased energy consumption in FY2019 due to reinforced storage temperature management and decreased floor space.
- Increased CO2 emissions in FY2019 due to increased emission factors for electricity, despite reduced electricity and fuel usage.
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
Greenhouse gas emissions & sustainability report data
In its 2020 reporting, TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. disclosed greenhouse gas emissions of 56.3K t-CO2 (FY2019). By scope: Scope 1: 24.8K t-CO2 (FY2019); Scope 2: 31.4K t-CO2 (FY2019). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
56.3K t-CO2 (FY2019)
2020
Water Usage
777.0K m3 (FY2019)
2020
Waste
4.4K tons (FY2019)
2020
Energy Use
1.0K MJ (FY2019)
2020
📊 Emissions by Scope (2020)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 24.8K t-CO2 (FY2019) |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 31.4K t-CO2 (FY2019) |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced average amount of CO2 emissions from Saitama Prefecture offices by 12.7% compared to the baseline year (FY2002-2004).
- Improved average annual energy consumption rate associated with transport by 0.7% against the baseline year.
- Achieved a 99.7% recycling rate for waste materials.
🎯 Climate & Sustainability Targets
📅 Medium-term
- Reduce CO2 emissions (Scope 1, 2) by 25% by FY2030 compared to FY2013.
🌱 ESG Focus Areas
EnvironmentalSocialGovernance